Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
60–89
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For CFD4870g participants: Previous enrollment and completion (Month 18 visit) of Study CFD4870g without early treatment discontinuation (lampalizumab or sham)
For GX29455 participants: Previous enrollment and completion (Week 24 visit) of Study GX29455 without early treatment discontinuation (lampalizumab or sham)
Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging
You may not be if
Early treatment and/or study discontinuation prior to completion of study CFD4870g (GX01456) and GX29455
Vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD) in the study eye
Subfoveal focal laser photocoagulation in the study eye
Treatment with Visodyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
Intravitreally (ITV) drug delivery (e.g., ITV corticosteroid injection, anti-angiogenic drugs, anticomplement drugs, or device implantation) in the study eye. Lampalizumab in study eye and ranibizumab in either eye are permitted
Any concurrent ocular or intraocular condition in the study eye that contraindicates the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications
Clareo Health | An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
